Login
Sign Up
Login
Sign Up
Features
Pricing
Reg.News
Contact
Login
Sign Up
Search
Providers
Companies
⨯
LIVE
Event in Progress:
Join Here
×
Search
Providers
Companies
⨯
Features
Pricing
Event Hub
Reg.News
Short Interest
Contact
All the news articles and press releases in one place.
UK Reg. News
German Reg. News
Search
Key Announcements
Results / Trading Updates
Get free RNS email alerts for@Model.CurrentFilterValue
Currently filtered for Novartis AG
Clear Filter
Sector
Automobile Industry
Banks
Basic Materials
Building & Construction
Chemicals
Consumer Discretionary Goods
Consumer Discretionary Services
Consumer Staple Goods
Consumer Staple Services
Discretionary Personal Goods
Discretionary Retail
Energy
ETFs
Finance
Financial Services
Food & Drink
Food Production
Health
Household Goods & DIY
Industrial
Industrial Equipment, Goods & Services
Insurance & Reinsurance
Investment Trusts
Leisure, Tourism & Travel
Media
Open-ended Funds
Other
Real Estate
Resources
Staple Retail
Technology
Telecoms
Trusts, ETFs & Funds
Utilities
Market Cap
Below £20m
£20m - £100m
£100m - £300m
£300m - £1bn
£1bn - £10bn
Over £10bn
Filters »
All
UK100
UK250
UK SmallCap
UK Other
Show:
10
25
50
100
«
1
2
3
4
5
»
Date / Time
Source
Ticker
Company
Sector
Market Cap
Announcement
18Jul18 16:30
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis Kisqali® now first and only CDK4/6 inhibitor indicated in US as first-line therapy specifically for premenopausal women; and as initial therapy with fulvestrant in postmenopausal women
18Jul18 06:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis delivers solid growth in second quarter and continues transformation to a focused medicines company
18Jul18 06:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis delivers solid growth in second quarter and continues transformation to a focused medicines company
29Jun18 13:10
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis receives positive CHMP opinion for Kymriah® for treating two aggressive blood cancers, marking important medical advance for patients in Europe
29Jun18 13:10
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis receives positive CHMP opinion for Kymriah® for treating two aggressive blood cancers, marking important medical advance for patients in Europe
29Jun18 06:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis announces intention to seek shareholder approval for 100% spinoff of Alcon eye care devices business; initiates share buyback of up to USD 5 bn
29Jun18 06:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis announces intention to seek shareholder approval for 100% spinoff of Alcon eye care devices business; initiates share buyback of up to USD 5 bn
28Jun18 21:30
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis presents new data demonstrating long-term efficacy, safety and tolerability of Aimovig® (erenumab) in patients with chronic and episodic migraine
27Jun18 21:30
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis International AG: Global study by Novartis and European Migraine and Headache Alliance reveals 60% of employed people with severe migraine miss, on average, a week of work per month
26Jun18 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis Clear about Psoriasis survey data highlights challenges psoriasis patients face to achieve goal of clear skin
18Jun18 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis International AG: Alcon AcrySof® IQ PanOptix® trifocal intraocular lens shows superior visual performance in head-to-head trial post-cataract surgery
16Jun18 10:30
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis JULIET trial of Kymriah demonstrates more than one-year durability of responses in adults with relapsed or refractory DLBCL
15Jun18 07:40
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis survey uncovers real-world impact of immune thrombocytopenia or ITP, a rare blood disease, on patients' quality of life
15Jun18 07:35
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis study of real-world data concludes Jakavi is associated with a reduction in risk of death and dangerous blood clots for patients with rare blood cancer
15Jun18 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Sandoz presents new long-term and switching data for biosimilars Zessly® (infliximab) and Erelzi® (etanercept) in rheumatoid arthritis
13Jun18 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis presents data to advance understanding of the role of IL-17A and reinforce Cosentyx® leadership in spondyloarthritis
07Jun18 21:05
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis announces JCO publication of Lutathera® NETTER-1 data showing significantly longer time to deterioration of key quality of life measures in patients with progressive midgut NETs
03Jun18 14:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Third Novartis Phase III trial shows Kisqali® combination therapy significantly improves PFS in HR+/HER2- advanced breast cancer
02Jun18 21:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
New Novartis data presented at ASCO find nearly half of CML patients treated with Tasigna® remain in remission almost three years after stopping therapy
01Jun18 13:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis completes sale of stake in consumer healthcare joint venture to GSK for USD13.0 billion
01Jun18 13:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis completes sale of stake in consumer healthcare joint venture to GSK for USD13.0 billion
01Jun18 12:44
GNW
0QLR:LON
Novartis AG
Health
208,186m
Sandoz receives positive CHMP opinion for proposed biosimilar adalimumab
01Jun18 12:40
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis receives positive CHMP opinion for Aimovig® (erenumab) for the prevention of migraine
01Jun18 12:40
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis receives positive CHMP opinion for Aimovig® (erenumab) for the prevention of migraine
30May18 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
FDA expedites review of Novartis drug Promacta® for first-line severe aplastic anemia (SAA)
28May18 15:30
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis International AG: Patient-reported outcomes tool revealed significant improvement in symptom frequency and quality of life domains with Entresto®
24May18 06:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Sandoz receives European Commission approval for Zessly® (infliximab) in gastroenterological, rheumatological and dermatological diseases
18May18 00:18
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis and Amgen announce FDA approval of Aimovig(TM) (erenumab), a novel treatment developed specifically for migraine prevention
18May18 00:14
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis and Amgen announce FDA approval of Aimovig(TM) (erenumab), a novel treatment developed specifically for migraine prevention
17May18 14:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis data at ASCO and EHA reinforce company's commitment to reimagining cancer
16May18 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
At the Meet Novartis Management investor event, Novartis highlights strategy to focus the company and drive sustainable growth
16May18 06:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis announces changes to the Executive Committee
16May18 06:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis announces changes to the Executive Committee
15May18 21:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis successfully completes acquisition of AveXis, Inc.
15May18 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis ARROW trial to assess mechanistic superiority of direct IL-17A inhibition (Cosentyx®) over IL-23 inhibition (Tremfya®*)
15May18 05:45
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis completes tender offer for all outstanding shares of AveXis, Inc.
11May18 23:24
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis announces FDA approval of Gilenya® as the first disease-modifying therapy for pediatric relapsing multiple sclerosis
07May18 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Alcon Cares Project 100 Commits to Reducing Cataract Blindness Globally
03May18 03:06
GNW
0QLR:LON
Novartis AG
Health
208,186m
Sandoz receives complete response letter from the US FDA for proposed biosimilar rituximab
02May18 21:05
GNW
0QLR:LON
Novartis AG
Health
208,186m
Sandoz receives complete response letter from the US FDA for proposed biosimilar rituximab
01May18 21:26
GNW
0QLR:LON
Novartis AG
Health
208,186m
Kymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphoma
01May18 21:26
GNW
0QLR:LON
Novartis AG
Health
208,186m
Kymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphoma
01May18 06:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis provides update on proposed acquisition of AveXis
01May18 06:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis provides update on proposed acquisition of AveXis
30Apr18 21:10
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis receives FDA approval of Tafinlar® + Mekinist® for adjuvant treatment of BRAF V600-mutant melanoma
30Apr18 21:05
GNW
0QLR:LON
Novartis AG
Health
208,186m
New Novartis Phase III data for brolucizumab demonstrate reliability of 12-week treatment interval
25Apr18 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis launches FocalView app, providing opportunity for patients to participate in ophthalmology clinical trials from home
20Apr18 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
New Novartis analyses at AAN show siponimod's efficacy on disability and cognition in secondary progressive MS patients
19Apr18 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis appoints John Tsai Head of Global Drug Development and Chief Medical Officer
19Apr18 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis appoints John Tsai Head of Global Drug Development and Chief Medical Officer
19Apr18 06:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis delivered a strong first quarter and acted to become a more focused medicines company
19Apr18 06:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis delivered a strong first quarter and acted to become a more focused medicines company
18Apr18 21:01
GNW
0QLR:LON
Novartis AG
Health
208,186m
Sandoz signs agreement with Pear Therapeutics to develop and commercialize prescription digital therapeutics for patients with substance use disorder and opioid use disorders
17Apr18 21:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis presents first-of-its-kind evidence at AAN reinforcing robust and consistent efficacy of AimovigTM* (erenumab) for migraine patients with multiple treatment failures
17Apr18 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis renews commitment to malaria elimination, investing USD 100 million to research and develop next-generation antimalarials
17Apr18 06:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis tender offer for AveXis commences
17Apr18 06:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis tender offer for AveXis commences
16Apr18 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis announces new analysis demonstrating Entresto helped preserve kidney function in patients with chronic heart failure, especially those with diabetes
09Apr18 05:45
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis enters agreement to acquire AveXis Inc. for USD 8.7 bn to transform care in SMA and expand position as a gene therapy and Neuroscience leader
09Apr18 05:45
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis enters agreement to acquire AveXis Inc. for USD 8.7 bn to transform care in SMA and expand position as a gene therapy and Neuroscience leader
04Apr18 16:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis announces JAMA Cardiology publication of data showing Entresto® improves physical and social activity in HFrEF patients versus enalapril
28Mar18 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis to present predictability data for brolucizumab in nAMD from pivotal HAWK and HARRIER trials at ARVO
27Mar18 06:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis to sell stake in consumer healthcare joint venture to GSK for USD13.0 billion to focus on strategic priorities
27Mar18 06:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis to sell stake in consumer healthcare joint venture to GSK for USD13.0 billion to focus on strategic priorities
23Mar18 12:51
GNW
0QLR:LON
Novartis AG
Health
208,186m
Sandoz receives positive CHMP opinion for proposed biosimilar infliximab
22Mar18 23:30
GNW
0QLR:LON
Novartis AG
Health
208,186m
Phase III data in The Lancet show Novartis siponimod significantly improves outcomes in patients with secondary progressive MS
22Mar18 16:30
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis drug Tasigna® approved by FDA to treat children with rare form of leukemia
20Mar18 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis teams up with Harvard to develop next generation biomaterial systems to deliver immunotherapies
12Mar18 06:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
NOVARTIS FINANCE S.A. : Directorate change
12Mar18 06:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis announces changes to the Executive Committee to support strategic priorities
07Mar18 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis expands alliance with Science 37 to advance virtual clinical trials program
06Mar18 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis' Xolair® recommended in new global chronic urticaria guideline
02Mar18 12:22
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis shareholders approve all resolutions proposed by Board of Directors at the Annual General Meeting
01Mar18 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis and Pear Therapeutics to develop digital therapeutics for patients with schizophrenia and multiple sclerosis
22Feb18 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Treatment with Novartis' Ultibro® Breezhaler® improved cardiac function in COPD patients with lung hyperinflation
16Feb18 21:05
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis new data show Cosentyx® improved quality of life over 5 years in two thirds of patients with moderate to severe plaque psoriasis
16Feb18 21:05
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis new Cosentyx® data confirms robust efficacy and quality of life improvements in scalp psoriasis
14Feb18 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis forms alliance to develop medicines for treating infectious diarrheal disease
13Feb18 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Sandoz announces US FDA approval and launch of Glatopa® 40 mg/mL three times-a-week generic option for relapsing forms of multiple sclerosis
08Feb18 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis receives FDA approval for Cosentyx® label update to include moderate-to-severe scalp psoriasis
01Feb18 21:05
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis completes subsequent offering period of the tender offer for Advanced Accelerator Applications S.A.
01Feb18 21:05
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis completes subsequent offering period of the tender offer for Advanced Accelerator Applications S.A.
31Jan18 22:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis announces NEJM publication of updated analysis from ELIANA trial showing longer-term durable remissions with Kymriah(TM) in children, young adults with r/r ALL
26Jan18 18:02
GNW
0QLR:LON
Novartis AG
Health
208,186m
Advanced Accelerator Applications Receives FDA Approval for Lutathera® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors
26Jan18 18:02
GNW
0QLR:LON
Novartis AG
Health
208,186m
Advanced Accelerator Applications Receives FDA Approval for Lutathera® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors
24Jan18 21:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis exclusively licenses first ophthalmology gene therapy in all markets outside the US, a milestone for patients with rare inherited vision loss
24Jan18 18:02
GNW
0QLR:LON
Novartis AG
Health
208,186m
NOVARTIS FINANCE S.A.: US Securities & Exchange Commission Form 20-F 2017
24Jan18 06:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis delivered good operational performance and landmark innovation in 2017, entering our next growth phase
24Jan18 06:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis delivered good operational performance and landmark innovation in 2017, entering our next growth phase
22Jan18 21:35
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis reports erenumab met all primary and secondary endpoints in unique Phase IIIb study in episodic migraine patients who have failed multiple prior preventive treatments
22Jan18 06:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis completes tender offer for Advanced Accelerator Applications S.A. and announces commencement of subsequent offering period
18Jan18 10:30
GNW
0QLR:LON
Novartis AG
Health
208,186m
Sandoz announces exclusive global collaboration with Biocon on next-generation biosimilars
17Jan18 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis granted US FDA Priority Review for Kymriah(TM) (tisagenlecleucel), formerly CTL019, for adults with r/r DLBCL
16Jan18 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis new data reinforces superiority of Cosentyx® versus Stelara®* in achieving skin clearance for psoriasis patients
16Jan18 06:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Sandoz regulatory submission for proposed biosimilar adalimumab accepted by FDA
11Jan18 06:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis appoints Elizabeth Barrett as Oncology Head
11Jan18 06:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis appoints Elizabeth Barrett as Oncology Head
09Jan18 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis advances head-to-head superiority trials of Cosentyx® versus Humira®* and proposed biosimilar adalimumab**
04Jan18 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis drug Promacta® receives FDA Breakthrough Therapy designation for first-line use in severe aplastic anemia (SAA)
03Jan18 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis Kisqali® received FDA Breakthrough Therapy designation for initial endocrine-based treatment in premenopausal women with HR+/HER2- advanced breast cancer
«
1
2
3
4
5
»
Date / Time
Source
Company
% Chg
18Jul18 16:30
GNW
Novartis AG
0.70%
Novartis Kisqali® now first and only CDK4/6 inhibitor indicated in US as first-line therapy specifically for premenopausal women; and as initial therapy with fulvestrant in postmenopausal women
18Jul18 06:00
GNW
Novartis AG
0.70%
Novartis delivers solid growth in second quarter and continues transformation to a focused medicines company
18Jul18 06:00
GNW
Novartis AG
0.70%
Novartis delivers solid growth in second quarter and continues transformation to a focused medicines company
29Jun18 13:10
GNW
Novartis AG
0.70%
Novartis receives positive CHMP opinion for Kymriah® for treating two aggressive blood cancers, marking important medical advance for patients in Europe
29Jun18 13:10
GNW
Novartis AG
0.70%
Novartis receives positive CHMP opinion for Kymriah® for treating two aggressive blood cancers, marking important medical advance for patients in Europe
29Jun18 06:00
GNW
Novartis AG
0.70%
Novartis announces intention to seek shareholder approval for 100% spinoff of Alcon eye care devices business; initiates share buyback of up to USD 5 bn
29Jun18 06:00
GNW
Novartis AG
0.70%
Novartis announces intention to seek shareholder approval for 100% spinoff of Alcon eye care devices business; initiates share buyback of up to USD 5 bn
28Jun18 21:30
GNW
Novartis AG
0.70%
Novartis presents new data demonstrating long-term efficacy, safety and tolerability of Aimovig® (erenumab) in patients with chronic and episodic migraine
27Jun18 21:30
GNW
Novartis AG
0.70%
Novartis International AG: Global study by Novartis and European Migraine and Headache Alliance reveals 60% of employed people with severe migraine miss, on average, a week of work per month
26Jun18 06:15
GNW
Novartis AG
0.70%
Novartis Clear about Psoriasis survey data highlights challenges psoriasis patients face to achieve goal of clear skin
18Jun18 06:15
GNW
Novartis AG
0.70%
Novartis International AG: Alcon AcrySof® IQ PanOptix® trifocal intraocular lens shows superior visual performance in head-to-head trial post-cataract surgery
16Jun18 10:30
GNW
Novartis AG
0.70%
Novartis JULIET trial of Kymriah demonstrates more than one-year durability of responses in adults with relapsed or refractory DLBCL
15Jun18 07:40
GNW
Novartis AG
0.70%
Novartis survey uncovers real-world impact of immune thrombocytopenia or ITP, a rare blood disease, on patients' quality of life
15Jun18 07:35
GNW
Novartis AG
0.70%
Novartis study of real-world data concludes Jakavi is associated with a reduction in risk of death and dangerous blood clots for patients with rare blood cancer
15Jun18 06:15
GNW
Novartis AG
0.70%
Sandoz presents new long-term and switching data for biosimilars Zessly® (infliximab) and Erelzi® (etanercept) in rheumatoid arthritis
13Jun18 06:15
GNW
Novartis AG
0.70%
Novartis presents data to advance understanding of the role of IL-17A and reinforce Cosentyx® leadership in spondyloarthritis
07Jun18 21:05
GNW
Novartis AG
0.70%
Novartis announces JCO publication of Lutathera® NETTER-1 data showing significantly longer time to deterioration of key quality of life measures in patients with progressive midgut NETs
03Jun18 14:00
GNW
Novartis AG
0.70%
Third Novartis Phase III trial shows Kisqali® combination therapy significantly improves PFS in HR+/HER2- advanced breast cancer
02Jun18 21:00
GNW
Novartis AG
0.70%
New Novartis data presented at ASCO find nearly half of CML patients treated with Tasigna® remain in remission almost three years after stopping therapy
01Jun18 13:00
GNW
Novartis AG
0.70%
Novartis completes sale of stake in consumer healthcare joint venture to GSK for USD13.0 billion
01Jun18 13:00
GNW
Novartis AG
0.70%
Novartis completes sale of stake in consumer healthcare joint venture to GSK for USD13.0 billion
01Jun18 12:44
GNW
Novartis AG
0.70%
Sandoz receives positive CHMP opinion for proposed biosimilar adalimumab
01Jun18 12:40
GNW
Novartis AG
0.70%
Novartis receives positive CHMP opinion for Aimovig® (erenumab) for the prevention of migraine
01Jun18 12:40
GNW
Novartis AG
0.70%
Novartis receives positive CHMP opinion for Aimovig® (erenumab) for the prevention of migraine
30May18 06:15
GNW
Novartis AG
0.70%
FDA expedites review of Novartis drug Promacta® for first-line severe aplastic anemia (SAA)
28May18 15:30
GNW
Novartis AG
0.70%
Novartis International AG: Patient-reported outcomes tool revealed significant improvement in symptom frequency and quality of life domains with Entresto®
24May18 06:00
GNW
Novartis AG
0.70%
Sandoz receives European Commission approval for Zessly® (infliximab) in gastroenterological, rheumatological and dermatological diseases
18May18 00:18
GNW
Novartis AG
0.70%
Novartis and Amgen announce FDA approval of Aimovig(TM) (erenumab), a novel treatment developed specifically for migraine prevention
18May18 00:14
GNW
Novartis AG
0.70%
Novartis and Amgen announce FDA approval of Aimovig(TM) (erenumab), a novel treatment developed specifically for migraine prevention
17May18 14:00
GNW
Novartis AG
0.70%
Novartis data at ASCO and EHA reinforce company's commitment to reimagining cancer
16May18 06:15
GNW
Novartis AG
0.70%
At the Meet Novartis Management investor event, Novartis highlights strategy to focus the company and drive sustainable growth
16May18 06:00
GNW
Novartis AG
0.70%
Novartis announces changes to the Executive Committee
16May18 06:00
GNW
Novartis AG
0.70%
Novartis announces changes to the Executive Committee
15May18 21:00
GNW
Novartis AG
0.70%
Novartis successfully completes acquisition of AveXis, Inc.
15May18 06:15
GNW
Novartis AG
0.70%
Novartis ARROW trial to assess mechanistic superiority of direct IL-17A inhibition (Cosentyx®) over IL-23 inhibition (Tremfya®*)
15May18 05:45
GNW
Novartis AG
0.70%
Novartis completes tender offer for all outstanding shares of AveXis, Inc.
11May18 23:24
GNW
Novartis AG
0.70%
Novartis announces FDA approval of Gilenya® as the first disease-modifying therapy for pediatric relapsing multiple sclerosis
07May18 06:15
GNW
Novartis AG
0.70%
Alcon Cares Project 100 Commits to Reducing Cataract Blindness Globally
03May18 03:06
GNW
Novartis AG
0.70%
Sandoz receives complete response letter from the US FDA for proposed biosimilar rituximab
02May18 21:05
GNW
Novartis AG
0.70%
Sandoz receives complete response letter from the US FDA for proposed biosimilar rituximab
01May18 21:26
GNW
Novartis AG
0.70%
Kymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphoma
01May18 21:26
GNW
Novartis AG
0.70%
Kymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphoma
01May18 06:00
GNW
Novartis AG
0.70%
Novartis provides update on proposed acquisition of AveXis
01May18 06:00
GNW
Novartis AG
0.70%
Novartis provides update on proposed acquisition of AveXis
30Apr18 21:10
GNW
Novartis AG
0.70%
Novartis receives FDA approval of Tafinlar® + Mekinist® for adjuvant treatment of BRAF V600-mutant melanoma
30Apr18 21:05
GNW
Novartis AG
0.70%
New Novartis Phase III data for brolucizumab demonstrate reliability of 12-week treatment interval
25Apr18 06:15
GNW
Novartis AG
0.70%
Novartis launches FocalView app, providing opportunity for patients to participate in ophthalmology clinical trials from home
20Apr18 06:15
GNW
Novartis AG
0.70%
New Novartis analyses at AAN show siponimod's efficacy on disability and cognition in secondary progressive MS patients
19Apr18 06:15
GNW
Novartis AG
0.70%
Novartis appoints John Tsai Head of Global Drug Development and Chief Medical Officer
19Apr18 06:15
GNW
Novartis AG
0.70%
Novartis appoints John Tsai Head of Global Drug Development and Chief Medical Officer
19Apr18 06:00
GNW
Novartis AG
0.70%
Novartis delivered a strong first quarter and acted to become a more focused medicines company
19Apr18 06:00
GNW
Novartis AG
0.70%
Novartis delivered a strong first quarter and acted to become a more focused medicines company
18Apr18 21:01
GNW
Novartis AG
0.70%
Sandoz signs agreement with Pear Therapeutics to develop and commercialize prescription digital therapeutics for patients with substance use disorder and opioid use disorders
17Apr18 21:00
GNW
Novartis AG
0.70%
Novartis presents first-of-its-kind evidence at AAN reinforcing robust and consistent efficacy of AimovigTM* (erenumab) for migraine patients with multiple treatment failures
17Apr18 06:15
GNW
Novartis AG
0.70%
Novartis renews commitment to malaria elimination, investing USD 100 million to research and develop next-generation antimalarials
17Apr18 06:00
GNW
Novartis AG
0.70%
Novartis tender offer for AveXis commences
17Apr18 06:00
GNW
Novartis AG
0.70%
Novartis tender offer for AveXis commences
16Apr18 06:15
GNW
Novartis AG
0.70%
Novartis announces new analysis demonstrating Entresto helped preserve kidney function in patients with chronic heart failure, especially those with diabetes
09Apr18 05:45
GNW
Novartis AG
0.70%
Novartis enters agreement to acquire AveXis Inc. for USD 8.7 bn to transform care in SMA and expand position as a gene therapy and Neuroscience leader
09Apr18 05:45
GNW
Novartis AG
0.70%
Novartis enters agreement to acquire AveXis Inc. for USD 8.7 bn to transform care in SMA and expand position as a gene therapy and Neuroscience leader
04Apr18 16:00
GNW
Novartis AG
0.70%
Novartis announces JAMA Cardiology publication of data showing Entresto® improves physical and social activity in HFrEF patients versus enalapril
28Mar18 06:15
GNW
Novartis AG
0.70%
Novartis to present predictability data for brolucizumab in nAMD from pivotal HAWK and HARRIER trials at ARVO
27Mar18 06:00
GNW
Novartis AG
0.70%
Novartis to sell stake in consumer healthcare joint venture to GSK for USD13.0 billion to focus on strategic priorities
27Mar18 06:00
GNW
Novartis AG
0.70%
Novartis to sell stake in consumer healthcare joint venture to GSK for USD13.0 billion to focus on strategic priorities
23Mar18 12:51
GNW
Novartis AG
0.70%
Sandoz receives positive CHMP opinion for proposed biosimilar infliximab
22Mar18 23:30
GNW
Novartis AG
0.70%
Phase III data in The Lancet show Novartis siponimod significantly improves outcomes in patients with secondary progressive MS
22Mar18 16:30
GNW
Novartis AG
0.70%
Novartis drug Tasigna® approved by FDA to treat children with rare form of leukemia
20Mar18 06:15
GNW
Novartis AG
0.70%
Novartis teams up with Harvard to develop next generation biomaterial systems to deliver immunotherapies
12Mar18 06:00
GNW
Novartis AG
0.70%
NOVARTIS FINANCE S.A. : Directorate change
12Mar18 06:00
GNW
Novartis AG
0.70%
Novartis announces changes to the Executive Committee to support strategic priorities
07Mar18 06:15
GNW
Novartis AG
0.70%
Novartis expands alliance with Science 37 to advance virtual clinical trials program
06Mar18 06:15
GNW
Novartis AG
0.70%
Novartis' Xolair® recommended in new global chronic urticaria guideline
02Mar18 12:22
GNW
Novartis AG
0.70%
Novartis shareholders approve all resolutions proposed by Board of Directors at the Annual General Meeting
01Mar18 06:15
GNW
Novartis AG
0.70%
Novartis and Pear Therapeutics to develop digital therapeutics for patients with schizophrenia and multiple sclerosis
22Feb18 06:15
GNW
Novartis AG
0.70%
Treatment with Novartis' Ultibro® Breezhaler® improved cardiac function in COPD patients with lung hyperinflation
16Feb18 21:05
GNW
Novartis AG
0.70%
Novartis new data show Cosentyx® improved quality of life over 5 years in two thirds of patients with moderate to severe plaque psoriasis
16Feb18 21:05
GNW
Novartis AG
0.70%
Novartis new Cosentyx® data confirms robust efficacy and quality of life improvements in scalp psoriasis
14Feb18 06:15
GNW
Novartis AG
0.70%
Novartis forms alliance to develop medicines for treating infectious diarrheal disease
13Feb18 06:15
GNW
Novartis AG
0.70%
Sandoz announces US FDA approval and launch of Glatopa® 40 mg/mL three times-a-week generic option for relapsing forms of multiple sclerosis
08Feb18 06:15
GNW
Novartis AG
0.70%
Novartis receives FDA approval for Cosentyx® label update to include moderate-to-severe scalp psoriasis
01Feb18 21:05
GNW
Novartis AG
0.70%
Novartis completes subsequent offering period of the tender offer for Advanced Accelerator Applications S.A.
01Feb18 21:05
GNW
Novartis AG
0.70%
Novartis completes subsequent offering period of the tender offer for Advanced Accelerator Applications S.A.
31Jan18 22:00
GNW
Novartis AG
0.70%
Novartis announces NEJM publication of updated analysis from ELIANA trial showing longer-term durable remissions with Kymriah(TM) in children, young adults with r/r ALL
26Jan18 18:02
GNW
Novartis AG
0.70%
Advanced Accelerator Applications Receives FDA Approval for Lutathera® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors
26Jan18 18:02
GNW
Novartis AG
0.70%
Advanced Accelerator Applications Receives FDA Approval for Lutathera® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors
24Jan18 21:00
GNW
Novartis AG
0.70%
Novartis exclusively licenses first ophthalmology gene therapy in all markets outside the US, a milestone for patients with rare inherited vision loss
24Jan18 18:02
GNW
Novartis AG
0.70%
NOVARTIS FINANCE S.A.: US Securities & Exchange Commission Form 20-F 2017
24Jan18 06:00
GNW
Novartis AG
0.70%
Novartis delivered good operational performance and landmark innovation in 2017, entering our next growth phase
24Jan18 06:00
GNW
Novartis AG
0.70%
Novartis delivered good operational performance and landmark innovation in 2017, entering our next growth phase
22Jan18 21:35
GNW
Novartis AG
0.70%
Novartis reports erenumab met all primary and secondary endpoints in unique Phase IIIb study in episodic migraine patients who have failed multiple prior preventive treatments
22Jan18 06:00
GNW
Novartis AG
0.70%
Novartis completes tender offer for Advanced Accelerator Applications S.A. and announces commencement of subsequent offering period
18Jan18 10:30
GNW
Novartis AG
0.70%
Sandoz announces exclusive global collaboration with Biocon on next-generation biosimilars
17Jan18 06:15
GNW
Novartis AG
0.70%
Novartis granted US FDA Priority Review for Kymriah(TM) (tisagenlecleucel), formerly CTL019, for adults with r/r DLBCL
16Jan18 06:15
GNW
Novartis AG
0.70%
Novartis new data reinforces superiority of Cosentyx® versus Stelara®* in achieving skin clearance for psoriasis patients
16Jan18 06:00
GNW
Novartis AG
0.70%
Sandoz regulatory submission for proposed biosimilar adalimumab accepted by FDA
11Jan18 06:00
GNW
Novartis AG
0.70%
Novartis appoints Elizabeth Barrett as Oncology Head
11Jan18 06:00
GNW
Novartis AG
0.70%
Novartis appoints Elizabeth Barrett as Oncology Head
09Jan18 06:15
GNW
Novartis AG
0.70%
Novartis advances head-to-head superiority trials of Cosentyx® versus Humira®* and proposed biosimilar adalimumab**
04Jan18 06:15
GNW
Novartis AG
0.70%
Novartis drug Promacta® receives FDA Breakthrough Therapy designation for first-line use in severe aplastic anemia (SAA)
03Jan18 06:15
GNW
Novartis AG
0.70%
Novartis Kisqali® received FDA Breakthrough Therapy designation for initial endocrine-based treatment in premenopausal women with HR+/HER2- advanced breast cancer
«
1
2
3
4
5
»
Date / Time
Company
% Chg
18Jul18 16:30
Novartis AG
0.70%
Novartis Kisqali® now first and only CDK4/6 inhibitor indicated in US as first-line therapy specifically for premenopausal women; and as initial therapy with fulvestrant in postmenopausal women
18Jul18 06:00
Novartis AG
0.70%
Novartis delivers solid growth in second quarter and continues transformation to a focused medicines company
18Jul18 06:00
Novartis AG
0.70%
Novartis delivers solid growth in second quarter and continues transformation to a focused medicines company
29Jun18 13:10
Novartis AG
0.70%
Novartis receives positive CHMP opinion for Kymriah® for treating two aggressive blood cancers, marking important medical advance for patients in Europe
29Jun18 13:10
Novartis AG
0.70%
Novartis receives positive CHMP opinion for Kymriah® for treating two aggressive blood cancers, marking important medical advance for patients in Europe
29Jun18 06:00
Novartis AG
0.70%
Novartis announces intention to seek shareholder approval for 100% spinoff of Alcon eye care devices business; initiates share buyback of up to USD 5 bn
29Jun18 06:00
Novartis AG
0.70%
Novartis announces intention to seek shareholder approval for 100% spinoff of Alcon eye care devices business; initiates share buyback of up to USD 5 bn
28Jun18 21:30
Novartis AG
0.70%
Novartis presents new data demonstrating long-term efficacy, safety and tolerability of Aimovig® (erenumab) in patients with chronic and episodic migraine
27Jun18 21:30
Novartis AG
0.70%
Novartis International AG: Global study by Novartis and European Migraine and Headache Alliance reveals 60% of employed people with severe migraine miss, on average, a week of work per month
26Jun18 06:15
Novartis AG
0.70%
Novartis Clear about Psoriasis survey data highlights challenges psoriasis patients face to achieve goal of clear skin
18Jun18 06:15
Novartis AG
0.70%
Novartis International AG: Alcon AcrySof® IQ PanOptix® trifocal intraocular lens shows superior visual performance in head-to-head trial post-cataract surgery
16Jun18 10:30
Novartis AG
0.70%
Novartis JULIET trial of Kymriah demonstrates more than one-year durability of responses in adults with relapsed or refractory DLBCL
15Jun18 07:40
Novartis AG
0.70%
Novartis survey uncovers real-world impact of immune thrombocytopenia or ITP, a rare blood disease, on patients' quality of life
15Jun18 07:35
Novartis AG
0.70%
Novartis study of real-world data concludes Jakavi is associated with a reduction in risk of death and dangerous blood clots for patients with rare blood cancer
15Jun18 06:15
Novartis AG
0.70%
Sandoz presents new long-term and switching data for biosimilars Zessly® (infliximab) and Erelzi® (etanercept) in rheumatoid arthritis
13Jun18 06:15
Novartis AG
0.70%
Novartis presents data to advance understanding of the role of IL-17A and reinforce Cosentyx® leadership in spondyloarthritis
07Jun18 21:05
Novartis AG
0.70%
Novartis announces JCO publication of Lutathera® NETTER-1 data showing significantly longer time to deterioration of key quality of life measures in patients with progressive midgut NETs
03Jun18 14:00
Novartis AG
0.70%
Third Novartis Phase III trial shows Kisqali® combination therapy significantly improves PFS in HR+/HER2- advanced breast cancer
02Jun18 21:00
Novartis AG
0.70%
New Novartis data presented at ASCO find nearly half of CML patients treated with Tasigna® remain in remission almost three years after stopping therapy
01Jun18 13:00
Novartis AG
0.70%
Novartis completes sale of stake in consumer healthcare joint venture to GSK for USD13.0 billion
01Jun18 13:00
Novartis AG
0.70%
Novartis completes sale of stake in consumer healthcare joint venture to GSK for USD13.0 billion
01Jun18 12:44
Novartis AG
0.70%
Sandoz receives positive CHMP opinion for proposed biosimilar adalimumab
01Jun18 12:40
Novartis AG
0.70%
Novartis receives positive CHMP opinion for Aimovig® (erenumab) for the prevention of migraine
01Jun18 12:40
Novartis AG
0.70%
Novartis receives positive CHMP opinion for Aimovig® (erenumab) for the prevention of migraine
30May18 06:15
Novartis AG
0.70%
FDA expedites review of Novartis drug Promacta® for first-line severe aplastic anemia (SAA)
28May18 15:30
Novartis AG
0.70%
Novartis International AG: Patient-reported outcomes tool revealed significant improvement in symptom frequency and quality of life domains with Entresto®
24May18 06:00
Novartis AG
0.70%
Sandoz receives European Commission approval for Zessly® (infliximab) in gastroenterological, rheumatological and dermatological diseases
18May18 00:18
Novartis AG
0.70%
Novartis and Amgen announce FDA approval of Aimovig(TM) (erenumab), a novel treatment developed specifically for migraine prevention
18May18 00:14
Novartis AG
0.70%
Novartis and Amgen announce FDA approval of Aimovig(TM) (erenumab), a novel treatment developed specifically for migraine prevention
17May18 14:00
Novartis AG
0.70%
Novartis data at ASCO and EHA reinforce company's commitment to reimagining cancer
16May18 06:15
Novartis AG
0.70%
At the Meet Novartis Management investor event, Novartis highlights strategy to focus the company and drive sustainable growth
16May18 06:00
Novartis AG
0.70%
Novartis announces changes to the Executive Committee
16May18 06:00
Novartis AG
0.70%
Novartis announces changes to the Executive Committee
15May18 21:00
Novartis AG
0.70%
Novartis successfully completes acquisition of AveXis, Inc.
15May18 06:15
Novartis AG
0.70%
Novartis ARROW trial to assess mechanistic superiority of direct IL-17A inhibition (Cosentyx®) over IL-23 inhibition (Tremfya®*)
15May18 05:45
Novartis AG
0.70%
Novartis completes tender offer for all outstanding shares of AveXis, Inc.
11May18 23:24
Novartis AG
0.70%
Novartis announces FDA approval of Gilenya® as the first disease-modifying therapy for pediatric relapsing multiple sclerosis
07May18 06:15
Novartis AG
0.70%
Alcon Cares Project 100 Commits to Reducing Cataract Blindness Globally
03May18 03:06
Novartis AG
0.70%
Sandoz receives complete response letter from the US FDA for proposed biosimilar rituximab
02May18 21:05
Novartis AG
0.70%
Sandoz receives complete response letter from the US FDA for proposed biosimilar rituximab
01May18 21:26
Novartis AG
0.70%
Kymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphoma
01May18 21:26
Novartis AG
0.70%
Kymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphoma
01May18 06:00
Novartis AG
0.70%
Novartis provides update on proposed acquisition of AveXis
01May18 06:00
Novartis AG
0.70%
Novartis provides update on proposed acquisition of AveXis
30Apr18 21:10
Novartis AG
0.70%
Novartis receives FDA approval of Tafinlar® + Mekinist® for adjuvant treatment of BRAF V600-mutant melanoma
30Apr18 21:05
Novartis AG
0.70%
New Novartis Phase III data for brolucizumab demonstrate reliability of 12-week treatment interval
25Apr18 06:15
Novartis AG
0.70%
Novartis launches FocalView app, providing opportunity for patients to participate in ophthalmology clinical trials from home
20Apr18 06:15
Novartis AG
0.70%
New Novartis analyses at AAN show siponimod's efficacy on disability and cognition in secondary progressive MS patients
19Apr18 06:15
Novartis AG
0.70%
Novartis appoints John Tsai Head of Global Drug Development and Chief Medical Officer
19Apr18 06:15
Novartis AG
0.70%
Novartis appoints John Tsai Head of Global Drug Development and Chief Medical Officer
19Apr18 06:00
Novartis AG
0.70%
Novartis delivered a strong first quarter and acted to become a more focused medicines company
19Apr18 06:00
Novartis AG
0.70%
Novartis delivered a strong first quarter and acted to become a more focused medicines company
18Apr18 21:01
Novartis AG
0.70%
Sandoz signs agreement with Pear Therapeutics to develop and commercialize prescription digital therapeutics for patients with substance use disorder and opioid use disorders
17Apr18 21:00
Novartis AG
0.70%
Novartis presents first-of-its-kind evidence at AAN reinforcing robust and consistent efficacy of AimovigTM* (erenumab) for migraine patients with multiple treatment failures
17Apr18 06:15
Novartis AG
0.70%
Novartis renews commitment to malaria elimination, investing USD 100 million to research and develop next-generation antimalarials
17Apr18 06:00
Novartis AG
0.70%
Novartis tender offer for AveXis commences
17Apr18 06:00
Novartis AG
0.70%
Novartis tender offer for AveXis commences
16Apr18 06:15
Novartis AG
0.70%
Novartis announces new analysis demonstrating Entresto helped preserve kidney function in patients with chronic heart failure, especially those with diabetes
09Apr18 05:45
Novartis AG
0.70%
Novartis enters agreement to acquire AveXis Inc. for USD 8.7 bn to transform care in SMA and expand position as a gene therapy and Neuroscience leader
09Apr18 05:45
Novartis AG
0.70%
Novartis enters agreement to acquire AveXis Inc. for USD 8.7 bn to transform care in SMA and expand position as a gene therapy and Neuroscience leader
04Apr18 16:00
Novartis AG
0.70%
Novartis announces JAMA Cardiology publication of data showing Entresto® improves physical and social activity in HFrEF patients versus enalapril
28Mar18 06:15
Novartis AG
0.70%
Novartis to present predictability data for brolucizumab in nAMD from pivotal HAWK and HARRIER trials at ARVO
27Mar18 06:00
Novartis AG
0.70%
Novartis to sell stake in consumer healthcare joint venture to GSK for USD13.0 billion to focus on strategic priorities
27Mar18 06:00
Novartis AG
0.70%
Novartis to sell stake in consumer healthcare joint venture to GSK for USD13.0 billion to focus on strategic priorities
23Mar18 12:51
Novartis AG
0.70%
Sandoz receives positive CHMP opinion for proposed biosimilar infliximab
22Mar18 23:30
Novartis AG
0.70%
Phase III data in The Lancet show Novartis siponimod significantly improves outcomes in patients with secondary progressive MS
22Mar18 16:30
Novartis AG
0.70%
Novartis drug Tasigna® approved by FDA to treat children with rare form of leukemia
20Mar18 06:15
Novartis AG
0.70%
Novartis teams up with Harvard to develop next generation biomaterial systems to deliver immunotherapies
12Mar18 06:00
Novartis AG
0.70%
NOVARTIS FINANCE S.A. : Directorate change
12Mar18 06:00
Novartis AG
0.70%
Novartis announces changes to the Executive Committee to support strategic priorities
07Mar18 06:15
Novartis AG
0.70%
Novartis expands alliance with Science 37 to advance virtual clinical trials program
06Mar18 06:15
Novartis AG
0.70%
Novartis' Xolair® recommended in new global chronic urticaria guideline
02Mar18 12:22
Novartis AG
0.70%
Novartis shareholders approve all resolutions proposed by Board of Directors at the Annual General Meeting
01Mar18 06:15
Novartis AG
0.70%
Novartis and Pear Therapeutics to develop digital therapeutics for patients with schizophrenia and multiple sclerosis
22Feb18 06:15
Novartis AG
0.70%
Treatment with Novartis' Ultibro® Breezhaler® improved cardiac function in COPD patients with lung hyperinflation
16Feb18 21:05
Novartis AG
0.70%
Novartis new data show Cosentyx® improved quality of life over 5 years in two thirds of patients with moderate to severe plaque psoriasis
16Feb18 21:05
Novartis AG
0.70%
Novartis new Cosentyx® data confirms robust efficacy and quality of life improvements in scalp psoriasis
14Feb18 06:15
Novartis AG
0.70%
Novartis forms alliance to develop medicines for treating infectious diarrheal disease
13Feb18 06:15
Novartis AG
0.70%
Sandoz announces US FDA approval and launch of Glatopa® 40 mg/mL three times-a-week generic option for relapsing forms of multiple sclerosis
08Feb18 06:15
Novartis AG
0.70%
Novartis receives FDA approval for Cosentyx® label update to include moderate-to-severe scalp psoriasis
01Feb18 21:05
Novartis AG
0.70%
Novartis completes subsequent offering period of the tender offer for Advanced Accelerator Applications S.A.
01Feb18 21:05
Novartis AG
0.70%
Novartis completes subsequent offering period of the tender offer for Advanced Accelerator Applications S.A.
31Jan18 22:00
Novartis AG
0.70%
Novartis announces NEJM publication of updated analysis from ELIANA trial showing longer-term durable remissions with Kymriah(TM) in children, young adults with r/r ALL
26Jan18 18:02
Novartis AG
0.70%
Advanced Accelerator Applications Receives FDA Approval for Lutathera® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors
26Jan18 18:02
Novartis AG
0.70%
Advanced Accelerator Applications Receives FDA Approval for Lutathera® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors
24Jan18 21:00
Novartis AG
0.70%
Novartis exclusively licenses first ophthalmology gene therapy in all markets outside the US, a milestone for patients with rare inherited vision loss
24Jan18 18:02
Novartis AG
0.70%
NOVARTIS FINANCE S.A.: US Securities & Exchange Commission Form 20-F 2017
24Jan18 06:00
Novartis AG
0.70%
Novartis delivered good operational performance and landmark innovation in 2017, entering our next growth phase
24Jan18 06:00
Novartis AG
0.70%
Novartis delivered good operational performance and landmark innovation in 2017, entering our next growth phase
22Jan18 21:35
Novartis AG
0.70%
Novartis reports erenumab met all primary and secondary endpoints in unique Phase IIIb study in episodic migraine patients who have failed multiple prior preventive treatments
22Jan18 06:00
Novartis AG
0.70%
Novartis completes tender offer for Advanced Accelerator Applications S.A. and announces commencement of subsequent offering period
18Jan18 10:30
Novartis AG
0.70%
Sandoz announces exclusive global collaboration with Biocon on next-generation biosimilars
17Jan18 06:15
Novartis AG
0.70%
Novartis granted US FDA Priority Review for Kymriah(TM) (tisagenlecleucel), formerly CTL019, for adults with r/r DLBCL
16Jan18 06:15
Novartis AG
0.70%
Novartis new data reinforces superiority of Cosentyx® versus Stelara®* in achieving skin clearance for psoriasis patients
16Jan18 06:00
Novartis AG
0.70%
Sandoz regulatory submission for proposed biosimilar adalimumab accepted by FDA
11Jan18 06:00
Novartis AG
0.70%
Novartis appoints Elizabeth Barrett as Oncology Head
11Jan18 06:00
Novartis AG
0.70%
Novartis appoints Elizabeth Barrett as Oncology Head
09Jan18 06:15
Novartis AG
0.70%
Novartis advances head-to-head superiority trials of Cosentyx® versus Humira®* and proposed biosimilar adalimumab**
04Jan18 06:15
Novartis AG
0.70%
Novartis drug Promacta® receives FDA Breakthrough Therapy designation for first-line use in severe aplastic anemia (SAA)
03Jan18 06:15
Novartis AG
0.70%
Novartis Kisqali® received FDA Breakthrough Therapy designation for initial endocrine-based treatment in premenopausal women with HR+/HER2- advanced breast cancer
«
1
2
3
4
5
»
Strapline
Strapline
Question 1
Answer 1
Question 2
Answer 2
Question 3
Answer 3
Question 4
Answer 4
Question 5
Answer 5
Question 6
Answer 6
Question 7
Answer 7
Question 8
Answer 8
Top
Home
Features
Pricing
Event Hub
Reg.News
Short Interest Tracker
Explore Content
Regions
UK
Rest of EMEA
N America
APAC
LatAm
Exchanges
Aquis Apex
Australian Securities Exchange
Canadian Securities Exchange
Euronext Paris
London Stock Exchange (domestic)
SIX Swiss Exchange
Sectors
Automobile Industry
Banks
Building & Construction
Chemicals
Discretionary Personal Goods
Discretionary Retail
Energy
ETFs
Financial Services
Food & Drink
Food Production
Health
Household Goods & DIY
Industrial Equipment, Goods & Services
Insurance & Reinsurance
Investment Trusts
Leisure, Tourism & Travel
Media
Open-ended Funds
Other
Real Estate
Resources
Staple Retail
Technology
Telecoms
Utilities
Small / Large Cap
UK100
UK250
UK Smallcap
UK Other Main Markets
Other
Private/EIS
EIS Single Company
EIS/SEIS Funds
IHT Products
SEIS Single Company
VCT Funds
Providers
Free/Commissioned
ACF Equity Research
Actio Advisors
Align Research
Atrium Research
BlytheRay
BNP Paribas Exane - Sponsored Research
Brand Communications
BRR Media
Calvine Partners
Capital Access Group
Capital Markets Brokers
Cavendish
Checkpoint Partners
Clear Capital Markets
Couloir Capital
Degroof Petercam
DirectorsTalk
Doceo
Edison
Equity Development
eResearch
Fidante Partners
Five Minute Pitch TV
focusIR
Fundamental Research Corp
Galliano’s Latin Notes
goetzpartners securities Limited
H2 Radnor
Hardman & Co
Holland Advisors
Hypothesis Research
Inbound Capital
Independent Investment Research
InterAxS Global
Kepler | Trust Intelligence
Liberum
London Stock Exchange
Magnitogorsk Iron and steel works
Mello Events
Mining Network
NuWays
Paul Scott
Peel Hunt
piworld.co.uk
Proactive
Progressive Equity Research
Quantum Research Group
QuotedData
RaaS - Research as a Service
Research Tree
Resolve Research
SEAL Advisors Ltd
ShareSoc
Shore Capital
Small Cap Consumer Research LLC
StockBox
Tennyson Securities
The AIC
The Life Sciences Division
Trinity Delta
Turner Pope Investments
UK Investor Group
Vox Markets
VSA Capital
WHIreland
Winterflood Securities
Yellowstone Advisory
Zeus Capital
High Net Worth Offering
Fox-Davies Capital
ACF Equity Research
Align Research
Allenby Capital
AlphaValue
Alternative Resource Capital
Arctic Securities
Arden Partners
Auctus Advisors
Baptista Research
BNP Paribas Exane - Sponsored Research
Canaccord Genuity
Cavendish
Couloir Capital
Dowgate Capital
First Berlin
First Sentinel
GSBR Research
Hannam & Partners
Hybridan
Kemeny Capital
Liberum
Longspur Clean Energy
Louis Capital
Magnitogorsk Iron and steel works
Medley Global Advisors
Northland Capital Partners
QuotedData Professional
Shard Capital
ShareSoc
Shore Capital
Singer Capital Markets
SP Angel
Stanford Capital Partners
Stifel FirstEnergy
Stockdale Securities
Tamesis Partners
Tennyson Securities
The Life Sciences Division
Turner Pope Investments
VSA Capital
WHIreland
Whitman Howard
Yellowstone Advisory
Zeus Capital
Institutional Offering
Fox-Davies Capital
ACF Equity Research
Align Research
Allenby Capital
Alternative Resource Capital
Arctic Securities
Arden Partners
Auctus Advisors
BNP Paribas Exane
BRR Media
Calvine Partners
Canaccord Genuity
Capital Access Group
Cavendish
Checkpoint Partners
Clear Capital Markets
Couloir Capital
Degroof Petercam
DirectorsTalk
Doceo
Dowgate Capital
Edison
Equity Development
eResearch
Fidante Partners
First Berlin
First Sentinel
Five Minute Pitch TV
Fundamental Research Corp
Galliano’s Latin Notes
Goodbody
H2 Radnor
Hannam & Partners
Hardman & Co
Holland Advisors
Hybridan
Inbound Capital
Independent Investment Research
InterAxS Global
Investec Bank
Kemeny Capital
Kepler | Absolute Hedge
Kepler | Trust Intelligence
Liberum
London Stock Exchange
Longspur Clean Energy
Magnitogorsk Iron and steel works
Mello Events
Mining Network
Northland Capital Partners
Numis
NuWays
Panmure Gordon
Peel Hunt
piworld.co.uk
Proactive
Quantum Research Group
QuotedData
RaaS - Research as a Service
Research Tree
Shard Capital
ShareSoc
Shore Capital
Singer Capital Markets
Small Cap Consumer Research LLC
SP Angel
Stanford Capital Partners
Stifel
StockBox
Tamesis Partners
Tennyson Securities
The AIC
The Life Sciences Division
Trinity Delta
UK Investor Group
Velocity Trade
Vox Markets
VSA Capital
WHIreland
Winterflood Securities
Yellowstone Advisory
Zeus Capital
Contact
Sign Up
Sign In
Share: